Rathinasabapathy Arthanareeswaran

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4059316/publications.pdf

Version: 2024-02-01

36	955	759233	677142
papers	citations	12 h-index	22 g-index

37	37	37	1695
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	6.7	183
2	Diminazene Attenuates Pulmonary Hypertension and Improves Angiogenic Progenitor Cell Functions in Experimental Models. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 648-657.	5.6	150
3	Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension. Hypertension, 2014, 64, 1248-1259.	2.7	126
4	In vitro glucose uptake activity of Aegles marmelos and Syzygium cumini by activation of Glut-4, PI3 kinase and PPARÎ³ in L6 myotubes. Phytomedicine, 2006, 13, 434-441.	5.3	80
5	Selective activation of angiotensin <scp>AT</scp>₂ receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. British Journal of Pharmacology, 2015, 172, 2219-2231.	5.4	75
6	Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L118-L126.	2.9	74
7	The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Frontiers in Physiology, 2018, 9, 180.	2.8	53
8	Therapeutic potential of adipose stem cellâ€derived conditioned medium against pulmonary hypertension and lung fibrosis. British Journal of Pharmacology, 2016, 173, 2859-2879.	5.4	44
9	Upregulation of Glut-4 and PPARÎ³ by an isoflavone from Pterocarpus marsupium on L6 myotubes: a possible mechanism of action. Journal of Ethnopharmacology, 2005, 97, 253-260.	4.1	35
10	Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension. Hypertension, 2018, 71, 1156-1163.	2.7	34
11	rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling. Frontiers in Physiology, 2018, 9, 271.	2.8	30
12	Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 59, 71-77.	3.1	18
13	KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models. International Journal of Molecular Sciences, 2021, 22, 5014.	4.1	11
14	Thromboxaneâ€“Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 596-607.	5.6	9
15	Rapid disease progress in a PVOD patient carrying a novel EIF2AK4 mutation: a case report. BMC Pulmonary Medicine, 2020, 20, 186.	2.0	7
16	Differential serum lipid distribution in IPAH and CHD-PAH patients. Respiratory Medicine, 2022, 191, 106711.	2.9	7
17	Expression of a Human Caveolin-1 Mutation in Mice Drives Inflammatory and Metabolic Defect-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 2020, 7, 540.	2.6	5
18	Association of cardiac injury with hypertension in hospitalized patients with COVID-19 in China. Scientific Reports, 2021, 11, 22389.	3.3	4

#	Article	IF	Citations
19	18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism: Clinical and Experimental, 2009, 58, 1503-1516.	3.4	3
20	7A.04. Journal of Hypertension, 2015, 33, e90.	0.5	3
21	Prevalence of Schistosoma japonicum-associated Pulmonary Hypertension in China: An Echocardiography-based Assessment. Annals of the American Thoracic Society, 2021, 18, 2095-2098.	3.2	3
22	Ubiquitin chains: a new way of screening for regulatory differences in pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-3.	1.7	1
23	PP.21.33. Journal of Hypertension, 2015, 33, e327-e328.	0.5	0
24	DISPARITIES IN HYPERTENSION PREVALENCE, AWARENESS, TREATMENT, CONTROL, AND ASSOCIATED FACTORS BETWEEN TUJIA AND HAN ETHNIC IN SOUTHWEST CHINA. Journal of the American College of Cardiology, 2019, 73, 1859.	2.8	0
25	Loss of KCNK3 in Mice Drives Susceptibility to Inflammatory Pulmonary Arterial Hypertension. , 2019, , .		0
26	Accumulation of Ceramide in Cardiomyocytes with BMPR2 Mutation Decreases Apoptosis by Disrupting Akt/GSK-3b Signaling Pathway. , 2019, , .		0
27	Complementary Embryonic and Adult Cell Populations Enhance Myocardial Repair in Rat Myocardial Injury Model. Stem Cells International, 2019, 2019, 1-11.	2.5	0
28	A First Report on Mass Cytometry Immunophenotyping of Peripheral Blood Mononuclear Cells in Pulmonary Arterial Hypertension. , 2020, , .		0
29	Overexpression of Msx1 in Mouse Lung Leads to Loss of Pulmonary Vessels Following Vascular Hypoxic Injury. Cells, 2021, 10, 2306.	4.1	0
30	Genetically Engineered Mesenchymal Stem Cells that Overexpress ACE2 or Angiotensinâ€(1â€“7) Show Enhanced Nitricâ€Oxide Production. FASEB Journal, 2013, 27, lb689.	0.5	0
31	Antiâ€oxidative and antiâ€inflammatory role of adipose stem cells in reversing pulmonary hypertension and associated cardiac remodeling (1090.9). FASEB Journal, 2014, 28, 1090.9.	0.5	0
32	Adipose Stem Cells attenuates Bleomycin induced Pulmonary Fibrosis. FASEB Journal, 2015, 29, LB750.	0.5	0
33	Diminazene, an ACE2 Activator Modulates Gut Microbiota and Provides Protection Against Pulmonary Hypertension. FASEB Journal, 2015, 29, LB749.	0.5	0
34	A Nonpeptide Angiotensin II Type 2 Receptor Agonist Prevents Pulmonary Fibrosis. FASEB Journal, 2015, 29, LB746.	0.5	0
35	Abstract 028: ACE2 Activator, Diminazene, Rebalances Gut Microbial Dysbiosis and Attenuates Pulmonary Hypertension. Hypertension, 2015, 66, .	2.7	0
36	C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction. , 2015, , .		0